Previous Page  18 / 232 Next Page
Information
Show Menu
Previous Page 18 / 232 Next Page
Page Background

Huyett P, Monaco SE, Choi SS, Simons JP. Utility of fine-needle aspiration biopsy in the

evaluation of pediatric head and neck masses.

Otolaryngol Head Neck Surg

. 2016;

154(5):928-935. EBM level 4........................................................................................190-197

Summary

: This article evaluates the use of fine-needle aspiration biopsy (FNAB) to assess

head and neck masses in the pediatric population. A total of 257 consecutive patients

underwent FNAB in the interventional radiology suite, operating room, clinic, or ward from

2007-2014. Most common diagnoses were reactive lymphadenopathy (38.5%), benign

thyroid colloid nodule (12.1%), malignancy (8.2%), and atypical mycobacterial infection

(5.8%). FNAB yielded an overall sensitivity of 94.6% and specificity of 97.7%.

Complication rate was 2.1%. Most patients required sedation or anesthesia for the FNAB

procedure. Negative FNAB can be utilized to provide reassurance to avoid unnecessary

surgery with its associated morbidity and cost.

Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of

oral propranolol in infantile hemangioma.

N Engl J Med

. 2015; 372(8):735-746. EBM

level 1..............................................................................................................................198-209

Summary

: This article summarizes the results of a randomized controlled trial on the use of

propranolol to treat complicated infantile hemangioma. A total of 460 patients were

randomized to receive placebo or one of four propranolol dosing regimens (1 or 3 mg/kg/day

for 3 or 6 months). The regimen of 3 mg/kg/day for 6 months was found to be the most

effective dosing regimen, with 60% of patients having complete or near-complete resolution

of hemangioma vs. 4% in the placebo group. Adverse events were more common in the

propranolol-treated groups (90%) compared to the placebo group (76%).